OncoMatch/Clinical Trials/NCT06507514
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
Is NCT06507514 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies blinatumomab and auto-HSCT "sandwich " strategy for b-cell acute lymphoblastic leukemia.
Treatment: blinatumomab and auto-HSCT "sandwich " strategy — Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the main method potentially curing adult B-ALL, but the high treatment-related mortality (NRM) affects overall survival (OS). Autologous stem cell transplantation (auto-HSCT) can significantly reduce NRM but has a higher relapse rate. Studies have confirmed that achieving MRD negativity before Auto-HSCT can effectively reduce post-transplant relapse, achieving similar efficacy to allo-HSCT. The efficacy of blinatumomab in clearing MRD has been confirmed. Therefore, using blinatumomab combined with Auto-HSCT for B-ALL patients seems to make it possible to achieve benefits in leukemia free survival（LFS） and OS. The investigators first conducted blinatumomab and auto-HSCT "sandwich " strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive expression (positive)
positive expression of CD19 in peripheral blood or bone marrow primary cells detected by flow cytometry
Prior therapy
Cannot have received: anti-cd19 therapy
Lab requirements
Kidney function
creatinine ≤ 1.6 mg/dl
Liver function
alt and ast ≤ 3 times the normal range and total bilirubin ≤ 2.0 mg/dl
Cardiac function
left ventricular ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify